SNES — SenesTech, Inc.
NASDAQ
Q3 2025 Earnings Call Summary
November 10, 2025
Summary of SenesTech Q3 2025 Earnings Call
1. Key Financial Results and Metrics
- Total Revenue: $690,000, a 43% increase year-over-year and a 10% increase sequentially.
- Evolve Product Revenue: Increased by 77%, accounting for 85% of total sales.
- ContraPest Revenue: Decreased by 31%, representing 15% of sales but remained flat compared to Q2.
- Gross Margin: Steady at 63%, with gross profit rising to $433,000 from $315,000.
- Operating Expenses: Decreased by 4% year-over-year and 12% sequentially, aided by the removal of $100,000 in one-time legal expenses.
- Adjusted EBITDA Loss: Improved to $1.2 million, the best in company history, compared to $1.4 million in the previous year.
2. Strategic Updates and Business Highlights
- E-commerce Growth: E-commerce sales represented 54% of total revenue, with a 55% year-over-year increase. Significant growth was noted from Amazon and new partnerships, including a launch on Lowe's e-commerce platform.
- Retail Expansion: Brick-and-mortar sales surged by 254% year-over-year, driven by partnerships with ACE Hardware and Bradley Caldwell.
- Municipal Market Adoption: Revenue from municipal deployments grew by 139%, with successful initiatives in cities like New York and Chicago.
- Production Capacity: Transition to a new facility in Phoenix aims to enhance production efficiency and meet future demand.
3. Forward Guidance and Outlook
- Management expressed confidence in achieving profitability without the need for further equity offerings, supported by a cash position of over $10 million.
- Continued focus on high-margin revenue growth and operational efficiency is expected to drive future performance.
- Anticipation of further expansion into brick-and-mortar retail and international markets, particularly following recent approvals in New Zealand.
4. Bad News, Challenges, or Points of Concern
- Legal Challenges: The company is facing a lawsuit from Liphatech regarding alleged IP infringement, which could lead to additional legal expenses and distract from business operations.
- ContraPest Performance: The decline in ContraPest sales raises concerns about reliance on Evolve for future revenue growth.
- International Market Delays: While progress is being made, approvals in international markets are taking longer than expected, potentially delaying revenue from these areas.
5. Notable Q&A Insights
- Lowe's Brick-and-Mortar Plans: Discussions are ongoing for potential test deployments in about 100 Lowe's stores by the end of Q2 2026.
- PMP Sales Growth: Pest Management Professionals (PMPs) accounted for 19% of sales, with expectations for significant growth as awareness of Evolve as a pest control solution increases.
- Pricing Strategy: The company is comfortable with its current pricing strategy for Evolve but is open to adjustments to secure larger orders if necessary.
- International Market Progress: New Zealand has granted approval for Evolve, and the company is optimistic about securing additional international approvals in the coming months.
Overall, SenesTech reported a strong quarter with significant revenue growth and operational improvements, while also facing challenges related to legal issues and product performance. The company remains focused on strategic expansion and profitability.
